Enhertu recommended for EU approval in early HER2-positive breast cancer
PureTech receives FDA Fast Track designation for LYT-200 in HR-MDS
Coiled Therapeutics completes enrolment in two AO-252 formulation cohorts
Myosin Therapeutics chosen for 2026-2027 NCI Investor Initiatives Showcase
GSK to acquire trispecific T cell-engager from Chimagen for multiple myeloma
Kelun-Biotech publishes phase III data for trastuzumab botidotin in HER2-positive breast cancer
AstraZeneca's Etcamah misses primary endpoint in Phase III breast cancer trial
GSK reports positive Jideytro data supporting potential first-line lung cancer use
Akeso presents positive results from registrational Phase III study of ivonescimab
ABL Diagnostics files bid to acquire IntegraGen
Tyra Biosciences declares positive Phase 2 results for oral dabogratinib in bladder cancer
Harbour BioMed partner raises USD225m to advance neoadjuvant immuno-oncology therapy porustobart
Kazia Therapeutics doses first patient in paediatric AT/RT study
Etcamah–CDK4/6 inhibitor combination approved in US for ESR1-mutated HR-positive breast cancer